Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$664.76K-$664.76KN/M vs Q3 2022 EPS Diluted$0.00$0.00— vs Q3 2022 Operating Income-$759,528N/M Operating Cash Flowderived-$562,709N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end